Posts tagged PODD
BTIG starts Insulet, Intersect at neutral

BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday.

Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events and key risks are hard to forecast in terms of timing. 

Read More